News
Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” ...
Beleaguered genetic testing company 23andMe announced Friday that it has reached an agreement to sell itself to TTAM Research ...
Lynozyfic’s global sales are projected to reach $707 million by 2031.
TTAM Research Institute, a non-profit public benefit company also founded by Wojcicki, won the auction with a $305 million ...
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...
Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN.
In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying opportunity?
This was the stock's second consecutive day of gains.
Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...
Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the ...
WilmerHale shouldn’t be permitted to represent a law professor making privacy-related recommendations about the sale of 23andMe’s customers’ genetic data while also performing work for bidder ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback